Single-cell RNA sequencing of terminal ileal biopsies identifies signatures of Crohn’s disease pathogenesis
12 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Single-cell RNA sequencing of terminal ileal biopsies identifies signatures of Crohn’s disease pathogenesis" is generating significant coverage in the Health category, with 14 articles from 12 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Technology Networks, Scientific Frontline, Genetic Engineering and Biotechnology News and Medical Xpress. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 133d ago.
Quick answers
Why is "Single-cell RNA sequencing of terminal ileal biopsies identifies signatures of C" trending?
Because 12 independent news sources published 14 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (14)
- Molecular Changes Persist After Inflammation Resolves in Crohn’s Disease Technology Networks · 136d ago
- GALT Immune Cell Mapping & Ulcerative Colitis Scientific Frontline · 136d ago
- Molecular Changes Persist After Inflammation Resolves in Crohn’s Disease Technology Networks · 136d ago
- Single-Cell RNA Sequencing Reveals Gene Activity Changes in Crohn’s Disease Genetic Engineering and Biotechnology News · 136d ago
- Immune cell circuit restores barrier function in inflammatory bowel disease Medical Xpress · 136d ago
- Molecular Changes Persist After Inflammation Resolves in Crohn’s Disease Technology Networks · 136d ago
- Immune Cell Circuit Restores Barrier Function in IBD Northwestern University · 136d ago
- Mapping immune cell interactions in gut tissue reveals changes in ulcerative colitis King's College London · 136d ago
- Gut Immune Cell Map Unveils Ulcerative Colitis Changes Mirage News · 136d ago
- 'Bouncer' immune cell discovered that fights Crohn's disease and IBD Glasgow Live · 136d ago
- NIH researchers identify regulatory cells that shield against inflammatory bowel disease National Institutes of Health (.gov) · 136d ago
- Gut cell study discovers lasting molecular scars of Crohn's disease News-Medical · 136d ago
- Mystery immune cell that fights IBD has been discovered Cambridge News · 136d ago
- Single-cell RNA sequencing of terminal ileal biopsies identifies signatures of Crohn’s disease pathogenesis Nature · 136d ago
Topics
Related trends
Rare and common genetic variants shape single-cell immune gene expression
New studies show rare and common DNA variants jointly steer immune cell activity, tightening the link between genetics and disease.
Protein fibers, a hallmark of Alzheimer's, spotted making genetic deliveries to sperm cells
Amyloid protein fibers typically associated with Alzheimer's disease have been observed delivering genetic material to sperm cells.
Squid Are Even More Alien-Like Than We Thought, With an Unmatched Ability to Change Genetic Expression
5 news sources are covering this Science story right now — PULSE is tracking how fast it spreads.
Germany's Merck buys Silence Therapeutics in $1.3 billion RNA drug deal
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial
AbbVie presents phase 2 trial data for its next-generation Crohn's disease therapy, ABBV-466.